Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mixed molecular subtypes coexist in estrogen receptor heterogenous primary breast cancers

ABSTRACT: Breast cancers show intratumor heterogeneity in estrogen receptor (ER) expression, but it is unclear whether cancer cells of different molecular subtypes (i.e. Luminal A, Luminal B, HER2-enriched, or Normal) can coexist in the same tumor. We performed spatial transcriptomic profiling of ER-negative, ER-low, and ER-high tumor cell regions of breast cancers that were 10-60% ER positive on routine immunohistochemistry using the GeoMxTM platform targeting 18,676 genes. We found that Luminal A and B molecular subtypes were intermixed in these tumors but there were no Basal-like cell populations. The ER-negative tumor regions were Luminal B-like and showed significantly lower expression of ESR1 and endocrine therapy sensitivity gene signatures but higher expression of inflammation and immune related genes, and also had higher recurrence scores indicating an endocrine-resistant but more chemotherapy sensitive phenotype. We also found that ESR1 strongly positive cells were enriched after preoperative chemotherapy in clinical trial tissues. These findings explain the worse clinical outcome of ER heterogenous breast cancers and suggest benefit from combined endocrine and chemotherapy strategies.

ORGANISM(S): Homo sapiens

PROVIDER: GSE290514 | GEO | 2026/03/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Activated Glucocorticoid Receptor is an Estrogen Receptor Silencer in ERα+ metastatic breast cancer [ChIP-seq]

Project description:Estrogen Receptor alpha (ERα)-positive, HER2-negative breast cancers are less aggressive than other subtypes and generally show good patient clinical outcome because they are likely to respond to endocrine therapies. Unfortunately, therapy-resistant metastases may develop and start an inexorable downhill course. ESR1 mutations leading to ligand-independent ERa activation and resistance to endocrine therapy are prevalent in 20 - 55% of patients with ER+ metastatic breast cancer. Here, we found that glucocorticoid receptor (GR) activation by dexamethasone in ESR1 mutant metastases-bearing mice decreases liver metastases, enhances chemotherapy responsiveness, and prolongs survival. Transcriptomic profiling and proteomics profiling revealed that GR activation not only downregulates estrogen reponse signature but also induces dramatic loss of ER itself, therefore uncovering an estrogen receptor silencing action of GR. ChIP-Seq analysis revealed that prolonged Dex treatment almost completely abrogates ER chromatin binding and that GR binds a subset of ER-related genes including ESR1 itself. This was accompanied by loss of H3K27 acetylation and enhancer acetylation, hence inhibiting transcription. Finally, we found that GR activation in patient-derived organoids reduces the number of ER+ cancer cells and ERα abundance, and predicts good outcome in patients with ER+ breast cancer, using publicly available data. These data imply that administration of synthetic glucocorticoids reduces ER+ cell proliferation, inhibits metastatic ability, enhances chemotherapy efficacy and hence can be beneficial for patients with ER+ metastatic breast cancer, particularly the treatment of refractory ESR1 mutant metastases.

2025-10-15 | GSE286891 | GEO

Activated Glucocorticoid Receptor is an Estrogen Receptor Silencer in ERα+ metastatic breast cancer [RNA-seq]

2025-10-15 | GSE286890 | GEO

Maintenance of Hormone Responsiveness in Luminal Breast Cancers by Suppression of Notch

Project description:Luminal breast cancers express estrogen (ER) and/or progesterone (PR) receptors and respond to hormone therapies. Basal-like “triple negative” (TN) cancers lack steroid receptors but are cytokeratin (CK) 5-positive and require chemotherapy. Here we show that over half of primary ER+PR+ breast cancers contain an ER–PR–CK5+ “luminobasal” subpopulation exceeding 1% of cells. Starting from ER+PR+ luminal cell lines, we generated novel lines with varying luminal to luminobasal-cell ratios and studied their molecular and biological properties. In luminal disease, luminobasal cells expand in response to antiestrogen or estrogen withdrawal therapies. The phenotype and gene signature of the hormone resistant cells matches that of clinical TN basal-like and claudin-low disease. Luminobasal-cell expansion in response to hormone therapies is regulated by Notch1 signaling and can be blocked by gamma-secretase inhibitors (GSI). Our data establish a previously unrecognized plasticity of ER+PR+ luminal breast cancers that, without genetic manipulation, mobilizes outgrowth of hormone-resistant basal-like disease in response to treatment. This undesirable outcome can be prevented by combining endocrine therapies with Notch inhibition. 24 array samples

2011-12-21 | E-GEOD-31870 | biostudies-arrayexpress

microRNAs and their target proteins associated with characteristics of estrogen receptor-positive breast cancer (mRNA data)

Project description:Recent analyses have identified heterogeneity in estrogen receptor (ER)-positive breast cancer. There are so-called luminal A and luminal B subtypes, and the characteristics, such as response to endocrine therapy and chemotherapy and prognosis, are different in these two subtypes of breast cancer. In this study, expression profiles of microRNAs (miRNAs) and mRNAs in ER-positive breast cancer tissues were compared between highly and incompletely endocrine responsive tumors by miRNA and mRNA microarrays. Unsupervised hierarchical clustering analyses revealed distinct expression patterns of miRNAs and mRNAs in these two groups. We identified one miRNA that was downregulated in highly endocrine responsive tumors and 8 miRNAs that were downregulated in incompletely endocrine responsive tumors, and target genes of these miRNAs were predicted using TargetScan and MiRanda. Protein expression patterns of the predicted target genes and the genes that were identified by mRNA expression profiling were analyzed in ER-positive breast cancer samples by immunohistochemistry. We identified a novel protein that might be associated with characteristics of ER-positive breast cancer.

2013-03-04 | GSE38279 | GEO

microRNAs and their target proteins are associated with characteristics of estrogen receptor-positive breast cancer (miRNA data)

2013-03-04 | GSE38278 | GEO

Maintenance of Hormone Responsiveness in Luminal Breast Cancers by Suppression of Notch

2011-12-21 | GSE31870 | GEO

Transcription profiling of breast cancer tumor samples to identify subtypes

Project description:Background Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A, luminal B, and ERBB2+. Results Based upon the analysis of 599 microarrays (five separate cDNA microarray datasets) using a novel approach, we present evidence in support of the most consistently identifiable subtypes of breast cancer tumor tissue microarrays being: ESR1+/ERBB2-, ESR1-/ERBB2-, and ERBB2+ (collectively called the ESR1/ERBB2 subtypes). We validate all three subtypes statistically and show the subtype to which a sample belongs is a significant predictor of overall survival and distant-metastasis free probability. Conclusion As a consequence of the statistical validation procedure we have a set of centroids which can be applied to any microarray (indexed by UniGene Cluster ID) to classify it to one of the ESR1/ERBB2 subtypes. Moreover, the method used to define the ESR1/ERBB2 subtypes is not specific to the disease. The method can be used to identify subtypes in any disease for which there are at least two independent microarray datasets of disease samples.

2006-11-09 | E-SMDB-3828 | biostudies-arrayexpress

Transcription profiling of human breast cancer samples to discover and validate breast cancer subtypes

2007-01-05 | E-SMDB-3830 | biostudies-arrayexpress

Transcription profiling of breast cancer tumor samples to identify subtypes

2006-11-10 | E-SMDB-3829 | biostudies-arrayexpress

Transcription profiling of human breast cancer samples to discover and validate breast cancer subtypes

2006-12-10 | E-SMDB-3831 | biostudies-arrayexpress